Pfizer disclosed its 2021 revenue guidelines for the first time on Tuesday, two months after the vaccine was approved.
Pfizer expects novel coronavirus pneumonia vaccine developed by BioNTech and BNT162b2 will generate revenue of US $15 billion this year, accounting for about 25% of its expected total revenue, and it is possible that the number will increase further as more agreements are signed.
At the same time, Pfizer raised its profit forecast for 2021, expecting adjusted diluted earnings per share to be between $3.1 and $3.2, higher than the original estimate of $3 to $3.1. Pfizer said bnt162b2’s adjusted pre tax profit is expected to exceed $4 billion, with a profit margin of more than 20%. As vaccine prices rise and costs fall, profits may further increase.
Pfizer CEO Albert bourla said that “what is more and more likely to happen” is that people need to strengthen the needle or more different vaccine formulations to deal with the new variant virus, which will bring about a “lasting” revenue stream.
If this is an open market, which means that doctors and citizens have the ability to choose the vaccines they want to receive, we will have a huge market share.
The latest research shows that some new coronavirus variants can evade the defense mechanism of the existing vaccine, thus making the vaccine ineffective. The official website of nature, an authoritative scientific journal, reported that the existing new coronavirus vaccine against the new coronavirus variant 501y.v2 from South Africa may be weaker than previously expected, and the virus may infect people who have previously infected the new coronavirus.
In late January, Pfizer said that it was actively preparing to adjust the vaccine formulation to cope with possible more complex virus variants, and it would take about six weeks to adjust the vaccine formulation to cope with new strains. But the specific time to market depends on the government regulatory department, which will decide what experimental data prove that the vaccine is effective and whether further clinical trials are needed.
As the first vaccine approved for emergency use in the United States, Pfizer has delivered 29 million doses of double dose vaccine to the U.S. government as of January 31. As of Monday, 17 million doses of the vaccine had been distributed, according to the Centers for Disease Control and prevention. Worldwide, Pfizer says it has provided 65 million doses of the vaccine.
Pfizer said on Tuesday that it plans to deliver 200 million doses of the vaccine to the United States by may, ahead of the initial forecast for July. Two billion doses of vaccine are expected to be delivered worldwide by the end of this year, he said.
Pfizer also released the fourth quarter and full year financial report of 2020, which showed that its revenue in the fourth quarter was 11.684 billion US dollars, a year-on-year increase of 12%; its net profit was 594 million US dollars, a year-on-year net loss of 337 million US dollars. Among them, the revenue from bnt162b2 was US $154 million, lower than the market expectation of US $684.1 million.
On Tuesday, Pfizer’s shares fell 2.26 percent to $34.99 at the close of the U.S. stock market.
Reprint indicated source：Spark Global Limited information